

1 **The effectiveness of repeating a social-norm feedback intervention to high prescribers**  
2 **of antibiotics in general practice: A national regression discontinuity design**

3

4 Michael RATAJCZAK<sup>1,2</sup>

5 Natalie GOLD\* D.Phil<sup>1,3</sup>

6 Simon HAILSTONE<sup>1</sup>

7 Tim CHADBORN PhD<sup>1</sup>

8

9 <sup>1</sup>Public Health England, Wellington House, 133-155 Waterloo Road, London, SE1 8UG,  
10 United Kingdom

11

12 \*Corresponding author: Natalie Gold, [natalie.gold@phe.gov.uk](mailto:natalie.gold@phe.gov.uk), 07967 839 044

13 Short running title: **repeating a social-norm feedback intervention**

14

15

16

17

18

19

20

21

22

23

24

25

---

<sup>2</sup>Present affiliation: Department of Linguistics and English Language, Lancaster University, Lancaster, LA1 4YL, United Kingdom

<sup>3</sup>Also affiliated with: Faculty of Philosophy, Radcliffe Humanities, Woodstock Road, Oxford, OX2 6GG, United Kingdom

26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62

## Structured synopsis

### Objectives

Unnecessary antibiotic prescribing contributes to antimicrobial resistance. A randomized controlled trial in 2014-5 showed that a letter from England’s Chief Medical Officer (CMO) to high prescribing General Practitioners (GPs), giving feedback about their prescribing relative to the norm, decreased antibiotic prescribing. The CMO sent further feedback letters in succeeding years. We evaluate the effectiveness of the repeated feedback intervention.

### Methods

Publicly available databases were used to identify GP practices whose antibiotic prescribing was in the top 20% nationally (the intervention group). In April 2017, GPs in every practice in the intervention group (n = 1,439) were sent a letter from the CMO. The letter stated that, “the great majority of practices in England prescribe fewer antibiotics per head than yours”. Practices in the control group received no communication (n = 5,986). We used a Regression Discontinuity Design to evaluate the intervention because assignment to the intervention condition was exogenous, depending on a ‘rating variable’. The outcome measure was the average rate of antibiotic items dispensed from April 2017 to September 2017.

### Results

The GP practices who received the letter changed their prescribing rates by -3.69% [95% CI = -2.29, -5.10];  $p < 0.001$ , representing an estimated 124,952 fewer antibiotic items dispensed. The effect is robust to different specifications of the model.

### Conclusions

Social-norm feedback from a high-profile messenger continues to be effective when repeated. It can substantially reduce antibiotic prescribing at low cost and at national scale. Therefore, it is a worthwhile addition to antimicrobial stewardship programmes.

63

64

## Introduction

65 Antimicrobial resistance (AMR) is a growing public health threat.<sup>1</sup> It is estimated that  
66 700,000 people die of resistant infections every year and that this number could rise to 10  
67 million lives a year by 2050, with common procedures, such as surgery and chemotherapy,  
68 becoming too dangerous to perform.<sup>2</sup> One cause of the problem is poor antimicrobial  
69 stewardship, with large quantities of antibiotics being prescribed to patients who do not need  
70 them.<sup>2,3</sup>

71

72 In the UK, about 80% of antibiotics are prescribed in primary care.<sup>4</sup> There is significant  
73 variation in prescribing between **General Practitioner (GP)** practices, which cannot be  
74 explained by practice demographics, indicating that many unnecessary antibiotics are being  
75 prescribed in primary care.<sup>5-7</sup> As a part of its AMR stewardship strategy, the UK Government  
76 aims to eventually give all health and care providers feedback in a format that is useable and  
77 relevant to support good practice.<sup>8</sup>

78

79 Giving GPs feedback on their practice's performance compared to other practices can  
80 decrease prescribing.<sup>9</sup> In September 2014, we ran a randomised controlled trial (RCT) in  
81 which the Chief Medical Officer (CMO) sent a feedback letter to 3,227 GPs stating that their  
82 practice was prescribing antibiotics at a higher rate than 80% of practices in its local area. As  
83 well as the social norm information, the letter presented three specific, feasible actions that  
84 the recipient could **take** to reduce unnecessary prescriptions of antibiotics: giving patients  
85 advice on self-care, offering a delayed prescription, and talking about the issue with other  
86 prescribers in his or her practice. The letter was accompanied by a copy of the "Treating your  
87 infection" leaflet (a part of the TARGET Antibiotic Toolkit),<sup>10</sup> **which aims to facilitate**  
88 **communication between prescriber and patient, and increase the patient's confidence to self-**  
89 **care.** Between October 2014 and March 2015, the practices in the intervention group  
90 dispensed 3.3% fewer antibiotic items relative to the control group. The rate of dispensing  
91 antibiotics differed significantly in every month in the study period, with no evidence of a  
92 trend. Therefore, the feedback letter was sent to the control group at the beginning of April  
93 2015.

94

95 The rise in AMR is an issue of international concern,<sup>1,2</sup> so the trial had an international  
96 impact. The intervention has already been adopted by **CMOs in Australia,<sup>11</sup> Northern**  
97 **Ireland,<sup>12</sup> and Canada,<sup>13,14</sup> and France is planning to follow suit.<sup>15</sup>**

98

99 Following on from the success of the RCT, the CMO **for England** has sent annual feedback  
100 letters to GPs whose practices are in the top 20% of prescribers, **each winter flu season.**  
101 However, there is a question of whether a repeated feedback intervention **continues** to be  
102 effective.<sup>16</sup> Because the CMO's feedback was targeted at a specific segment of  
103 practitioners—the top 20%—it is possible to use a regression discontinuity design to evaluate  
104 the subsequent feedback intervention.

105  
106  
107

## Method

### 108 **Intervention: Letters to High Antibiotic Prescribers**

109 The CMO sent her feedback letter on antibiotic prescribing rates to GPs in April 2017. The  
110 feedback letters were sent to 6,318 individual GPs in 1,439 different GP practices with high  
111 antibiotic prescribing rates. Practices were allocated to the intervention arm if they were in  
112 the top 20% of prescribers for the twelve months prior to the end of the intervention (Oct  
113 2015 –Sep 2016), as judged using a prescribing indicator which divides Antibacterial Items  
114 by STAR-PU (Specific Therapeutic group Age-sex Related Prescribing Units) weightings.  
115 This means that the prescribing rate is adjusted to **take into account some of** the  
116 demographics of the GP practice.

117

118 The letters differed slightly from the 2014 trial:<sup>9</sup> NHS Local Areas no longer exist, so each  
119 practice's prescribing was compared to that of practices in England; and **additional guidance**  
120 **was** presented in a box on the right-hand side, instead of in the middle of the letter. There  
121 were six different letters (**Supplementary Data: Figures S1-S6**). The letters were tailored  
122 according to GP practice prescribing rate, change in prescribing over time, and whether they  
123 were previously sent feedback. Specifically, the top 11-20% practices with increasing  
124 prescribing rates were told 'The great majority (80%) of practices in England prescribe fewer  
125 antibiotics per head than yours. Most other practices have reduced their prescribing rates  
126 since 2013/14 but yours has increased' (**Letter 1: Figures S1-S2**); the rest of the top 20% were  
127 simply told 'The great majority (80%) of practices in England prescribe fewer antibiotics per  
128 head than yours' (**Letter 2: Figures S3-S4**). Finally, the top 10% of practices were told 'The  
129 great majority (90%) of practices in England prescribe fewer antibiotics per head than yours'  
130 (**Letter 3: Figures S5-S6**). When a practice had received a previous letter, the CMO noted, 'I  
131 have written to your practice previously', **so there were two variants of each letter, A and B.**  
132 **Table 1 shows the key differences between the letter variants.** As in the 2014 trial, the letter  
133 was accompanied by a copy of the TARGET "Treating your infection" leaflet  
134 (**Supplementary Data: Figure S7**).

135

### 136 **Regression Discontinuity Design**

137 **We decided to use Regression Discontinuity Design (RDD) to analyse the effects of our**  
138 **intervention instead of more conventional analytical approaches, such as interrupted time**  
139 **series (ITS) and difference-in-difference design. RDD is a standard approach for evaluating**  
140 **interventions.<sup>17</sup>** In an RDD, the assignment of participants to the intervention versus the  
141 control condition is exogenous, depending on whether a numerical 'rating variable' falls  
142 above or below a certain threshold. Participants scoring above the threshold are assigned to  
143 one group, such as the treatment, whereas those scoring below the threshold are assigned to  
144 another group, for example, the control. The assumption behind RDD is that, in a window  
145 around the threshold (the 'bandwidth'), observations on each side are on average identical in  
146 terms of all pre-treatment variables. There is a 'local randomization' in this window. There is  
147 also a discontinuity in the probability of treatment at the threshold between the treatment

148 group and the control. Therefore, if there is a corresponding discontinuity in the intercept of  
149 the regression of the outcome variable on the predictor at the threshold level, the change in  
150 outcome is attributed to the effect of the intervention.<sup>18</sup> Critically, RDD can provide evidence  
151 for the causal effect of an intervention because, controlling for the value of the rating  
152 variable, it is possible to account for unobserved differences between the treatment and the  
153 control group.<sup>19-21</sup>

154  
155 RDD a quasi-experimental evaluation method that can be used in cases where it would be  
156 impractical or unethical to assign participants to different groups,<sup>17</sup> for example, the impact  
157 of prisons on recidivism, and the impact of health insurance on improving service  
158 utilisation.<sup>22, 23</sup> In the present study, it is unethical to experimentally assign GP practices to  
159 different experimental groups since we have reason to believe that the treatment is effective,  
160 given the evidence from our previous trial.<sup>9</sup> Therefore we evaluate the intervention using a  
161 sharp RDD, a variation of the RDD where the rating variable perfectly predicts treatment  
162 allocation.<sup>24</sup> This means that the probability of treatment changes from 0 to 1 at the threshold.  
163 The rating variable was the prescribing indicator (average antibiotic prescribing rate adjusted  
164 for STAR-PU) and the threshold was 1.14825 antibiotic items dispensed per STAR-PU, the  
165 cut-off point separating the 20% of highest prescribers from the remaining GP practices. We  
166 used R,<sup>25</sup> specifically function call RDestimate of package rdd,<sup>26</sup> to build our RDD models.

### 167 168 **Bandwidth Size**

169 One of the critical steps in RDD is selecting the bandwidth size around the threshold to create  
170 the localised sample.<sup>27</sup> This is because narrower bandwidths increase comparability between  
171 cases on each side of the threshold while decreasing the statistical power, whereas wider  
172 bandwidths increase power at the cost of decreasing internal validity by including cases  
173 further away from the threshold. Hence it is necessary to select the appropriate bandwidth,  
174 which finds the balance between precision and power. The Imbens-Kalyanaraman algorithm  
175 provides a data driven, asymptotically optimal bandwidth for RDD.<sup>27</sup> The calculated  
176 bandwidth is tailored to specific features of the RDD setting. Using package rdd,<sup>26</sup> in R,<sup>25</sup> we  
177 calculated the optimal bandwidth size to create the localised sample around the threshold that  
178 minimised bias and optimised precision. The optimal bandwidth differed for different models  
179 considered. For the most parsimonious model (Table 2) the optimal bandwidth was 0.5234  
180 antibiotic items dispensed per STAR-PU. Thus, practices within 0.5234 points of the  
181 threshold in either direction were included in the local linear regression analyses. The number  
182 of practices within this bandwidth (n = 6,524), used to calculate the most plausible estimate  
183 of the Local Average Treatment Effect (LATE), provided sufficient power to detect a  
184 statistically significant effect at  $p < 0.001$ .

### 185 186 **Data**

187 The data for this study came from the Public Health England data warehouse (originally  
188 collected by the NHS Business Services Authority and NHS Digital).<sup>28, 29</sup> These data consist  
189 of all GP practices in England who were sent the April 2017 CMO feedback letter (n =  
190 1,439), as well as the remaining practices who served as the control group (n = 5,986). To  
191 account for differences in prescribing due to seasonality, we defined our baseline measure,

192 which we used to determine the percentile of prescribers that each practice was in, as **mean-**  
193 **STAR-PU-adjusted** prescribing rate from October 2015 to September 2016. The outcome  
194 measure was **mean-STAR-PU-adjusted** rate of antibiotic items dispensed during the  
195 intervention period, April 2017 to September 2017.

196

### 197 **Data Preparation**

198 We calculated our baseline and outcome measures using the same quarterly Antibacterial  
199 Items/STAR-PU weightings that we used to select the practices for letter allocations. For the  
200 analysis we coded all the practices that received the letter (20% of **highest** prescribers) as the  
201 intervention group. The remaining practices, which did not receive the letter because they  
202 were in the 21 – 100% **of** prescribers, were the control group.

203

204 We kept the GP practices in the central 99% of the records of both baseline and outcome  
205 measures. This means that we removed practices that were classified as outliers due to their  
206 extremely high or low rates of prescribing (**n = 133**), or due to extremely large/small patient  
207 populations (**n = 57**). We also removed practices due to instances of missing prescribing data  
208 between October 2015 to September 2017 (**n = 231**).

209

210 Since the CMO letters were sent only to the highest 20% of prescribers, we aimed to set the  
211 RDD cut-off threshold at the 5th quintile. However, the threshold was adjusted to 1.1812  
212 from 1.1813 to account for the removal of some practices (**n = 9**) during data preparation  
213 because of practice changes over the intervention period or because of lack of STAR-PU data  
214 for the duration of the intervention period. Overall, we removed 430 GP practices. This  
215 resulted in the total sample of 6,995 GP practices, 1,378 of which received the letter in April  
216 2017 (treatment group), and 5,617 of which did not (control group).

217

218

## **Results**

219 Table 2 and Figure 1 demonstrate the results of the simplest model, where the baseline  
220 measure (average prescribing rate adjusted for STAR-PU during the period October 2015 to  
221 September 2016) is regressed on the outcome measure (average prescribing rate adjusted for  
222 STAR-PU during the six month of the intervention period). The RDD estimates can be  
223 interpreted as weighted average effects of treatment across all GP practices. The LATE  
224 **estimate**, which **is** calculated using the optimal bandwidth, **shows** that the letter intervention  
225 resulted in a significant discontinuity ( $\beta = -0.016$ ,  $SE = 0.003$ ,  $z = -5.141$ ,  $p < 0.001$ ); the GP  
226 practices who received the letter changed their prescribing rates by approximately -3.69%  
227 [95% CI = **-2.29, -5.10**]. **However, it is important to acknowledge that deprivation levels**  
228 **could vary between the local areas covered by GP practices in the treatment and the control**  
229 **groups. This variation could affect prescribing rates of GP practices. Thus, we adjusted the**  
230 **estimates for this potential variation in deprivation using deprivation indices.<sup>30</sup> We found that**  
231 **the intervention effect was not sensitive to the inclusion of a deprivation measure (Table 3).**  
232 Moreover, although the effect size varies depending on the bandwidth used, overall the effect  
233 remains robust to halving or doubling the bandwidth and therefore including a different

234 number of observations for both the unadjusted and adjusted estimates. This indicates that our  
235 findings are likely to be relatively reliable and valid.

236

237 We also built an RDD with a categorical variable specifying GP practices' allocation to one  
238 of six letters or the control group, to examine whether the intervention was effective across  
239 all letter types. We present the estimates for each letter type, both unadjusted and adjusted for  
240 deprivation, in (Table 4). The four letters sent to the top 11-20% (Letters 1A, 1B, 2A, and  
241 2B) were estimated to be relatively effective at reducing antibiotic prescribing (1A: -5.21%  
242 [95% CI = -1.98, -8.45]; 1B: -4.75% [95% CI = -2.96, -6.54]; 2A: -2.32% [95% CI = -0.45, -  
243 4.18]; 2B: -3.81% [95% CI = -1.86, -5.76]), with the letters sent to those practices whose  
244 prescribing was increasing being most effective. However, for the practices in the top 10%  
245 (Letters 3A and 3B) our estimates of the intervention in the general population were not clear.  
246 This is because the effects of the intervention for the two letter types were not statistically  
247 significant (3A: -2.13% [95% CI = 0.76, -5.02]; 3B: 1.47% [95% CI = 7.24, -4.30]).

248

249 Based on a predicted 3.69% reduction in antibiotic prescribing for the intervention group over  
250 a six-month period (Table 2), an estimated 124,952 fewer antibiotic items were dispensed  
251 during the study as a result of the letter intervention. Specifically, we estimated that  
252 3,386,243 antibiotic items would have been dispensed without the intervention by the GP  
253 practices in the intervention arm, whereas 3,261,291 antibiotic items were found to have been  
254 dispensed with the intervention.

255

256 To estimate the effect on direct prescribing costs for the public sector, we considered the  
257 basic cost of a drug as used in primary care during the intervention period, specifically the  
258 average net ingredient cost (NIC) of £8.29 per antibiotic item.<sup>31</sup> The NIC does not take into  
259 account dispensing costs, fees or prescription charge income. Thus, we assumed that 10.2%  
260 of antibiotics (12,745) incurred a £8.60 prescription charge (in line with the overall  
261 exemption rate for April to September 2017), which we deducted from the cost estimate.<sup>31-33</sup>  
262 We also added the £1.25 per item professional fee payable to pharmacy contractors by NHS  
263 England in 2017.<sup>32, 33</sup> The cost of printing and mailing to 6,318 GPs in 1,439 practices, which  
264 was deducted from the savings estimate to produce a net savings estimate, was £5,527. This  
265 equates to £0.04 per prescription prevented during the study period. Overall, the predicted  
266 reduction in the number of prescribed antibiotics during the intervention is estimated to have  
267 generated net savings of £1,076,908 (£991,842 if adjusted for practice deprivation) in NIC  
268 and dispensing costs for the public sector.

269

270

## Discussion

271 RDD analysis shows that the 2017 CMO feedback letter reduced antibiotic prescribing by  
272 3.69%, which is similar to the 3.3% reduction in prescribing that was found in the 2014  
273 RCT.<sup>9</sup> The finding that repeated feedback continues to have an effect on antibiotic  
274 prescribing is consistent with other trials that have used repeated feedback, in medicine and  
275 in other policy areas.<sup>34, 35</sup> A systematic review finds that repeated feedback is more effective  
276 than single instances in healthcare settings.<sup>36</sup> However, these studies tend to analyse the

277 repeated feedback as a single intervention. To our knowledge, this is the first study that  
278 investigates whether a successful antibiotic feedback intervention can be as effective when  
279 repeated. Our results suggest that the social-norm feedback intervention can be successfully  
280 implemented multiple times.

281

282 There were many anti-microbial stewardship interventions happening in the UK in 2017-8.  
283 For instance, the Quality Premium gave financial incentives for reducing inappropriate  
284 prescribing; the TARGET toolkit was developed, a suite of resources that health-care workers  
285 can use to support patients to self-care; the Antibiotic Guardian campaign encouraged  
286 professionals to pledge to prescribe appropriately; and the Keep Antibiotic Working  
287 campaign was a patient facing advertising campaign.<sup>37</sup> Therefore, it may not be a surprise  
288 that antibiotic prescribing in primary care is decreasing.<sup>37</sup> However, the RDD is a quasi-  
289 experimental method of evaluation and the difference between the groups within the  
290 bandwidth is whether or not they received a letter, so we can attribute the 3.69% difference in  
291 prescribing between groups to the letter.

292

293 The intervention decreased prescribing amongst practices in the top 11-20%, especially those  
294 whose prescribing had been increasing in the year beforehand; this decrease was observed  
295 both in practices that had received a letter in the previous year and in practices that had not  
296 received a letter. However, it did not have a significant effect on practices in the top 10%.  
297 There are two types of possible explanation for this difference. First, there may have been  
298 something specific to the practices in the top 10%. Our adjustments accounted for the age and  
299 sex of the practices' patient population (STAR-PU) and their deprivation. However, there  
300 may have been other relevant factors that affect antibiotic prescribing, for instance prevalence  
301 of Chronic Obstructive Pulmonary Disorder or smoking, which were not captured in our  
302 models. Second, there may have been something about the message, which was more extreme  
303 for the top 10%. Telling GPs that their practice was in the top 10% of prescribers may have  
304 made their prescribing seem so disproportionate that they felt they could not do anything  
305 about it. The forceful message may have provoked psychological reactance, leading to  
306 negative attitudes towards the message and the generation of counterarguments, resulting in a  
307 lower behavioural intention to comply with the message.<sup>38-40</sup> Alternatively, while highly  
308 credible sources are more persuasive the more discrepant the receiver finds the message,  
309 moderately credible sources may be less persuasive when they send a highly discrepant  
310 message. If the CMO is only perceived as a moderately credible source, then the highly  
311 discrepant message received by the top 10% of prescribers may have been less persuasive  
312 than the less discrepant message received by the top 20%.<sup>41, 42</sup>

313

314 The intervention has already been used successfully in Australia, Ireland, and Canada, and  
315 France is planning to follow suit.<sup>11-15</sup> The countries that are implementing the intervention are  
316 fairly similarly culturally, they are all Western Educated Industrialized Rich Democracies  
317 (WEIRD).<sup>43</sup> It is possible that the effect of descriptive norms and therefore the international  
318 applicability of the intervention might vary between cultures. The strength of social norms in  
319 countries is thought to vary along a spectrum that ranges from 'tight' (have many strong  
320 norms and a low tolerance of deviant behaviour) to 'loose' (have weak social norms and a



321 high tolerance of deviant behaviour), and the UK, Australia, and France are in the middle of  
322 the spectrum.<sup>44, 45</sup> We might anticipate that the feedback letter intervention would be least  
323 effective in the countries with the loosest cultures (Estonia, Hungary, and Ukraine) and most  
324 effective in countries with the tightest cultures (India, Malaysia, Pakistan, Singapore, and  
325 South Korea). However, this is very speculative because the way that primary care is  
326 delivered, and that antibiotic prescribing occurs, may differ in these countries and because the  
327 UK has lower antibiotic prescribing than many countries.<sup>46</sup>

328

329 Our study has several limitations. First, the STAR-PU data is calculated on a quarterly rather  
330 than a monthly basis. Therefore, it is not currently possible to detect the exact extent of the  
331 discontinuity in a specific month of an intervention. The strength of the intervention may  
332 differ over the course of the outcome, but this may be masked by the three-month average of  
333 the outcome variable. Thus, we can conclude that there was a difference in prescribing over  
334 the entire evaluation period, but we are not able to detect time trends, if they exist. **Future  
335 studies, conditional on fine-grained longitudinal data, could utilise ITS to address that.**

336

337 Second, the RDD tends to be less precise than a comparable RCT. An RDD sample has to be  
338 at least 2.4 times greater than that of an equivalent randomised trial in order to achieve the  
339 same level of precision.<sup>24</sup> Moreover, the precision of an RDD is sensitive to the distribution  
340 of scores around the threshold. The non-parametric method of calculating the bandwidth uses  
341 observations close to the threshold.<sup>27</sup> Therefore, although our data-driven bandwidth choice is  
342 claimed to be optimal, it ignores the observations outside of the bandwidth. This is why non-  
343 parametric methods tend to be less precise than parametric methods for a given sample.<sup>24</sup> In  
344 the present study, we accounted for this by looking at the estimates of **different RDD models**  
345 given different bandwidths.

346

347 **In conclusion,** our results suggest that it could be worthwhile for antimicrobial stewardship  
348 programmes to incorporate regular **social-norm** feedback into their activities, as a part of their  
349 strategy. **We found that, on average feedback was effective, but it was not effective for the  
350 top 10% of prescribing practices, and future research could investigate why.** Individual-level  
351 feedback is likely to be even more effective, but data by prescriber are not yet centrally  
352 available in England. The effectiveness of social-feedback may also generalize to other  
353 domains, including antibiotic prescribing that occurs outside of primary care and other areas  
354 of medicine where evidence suggests that there may be high levels of inappropriate  
355 prescribing or over-use of clinical tests.

356

## 357 **Funding**

358 Public Health England.

359

## 360 **Transparency declaration**

361 Natalie Gold affirms that this manuscript is an honest, accurate, and transparent account of  
362 the study being reported; that no important aspects of the study have been omitted; and that  
363 any discrepancies from the study as planned have been explained. There are no conflicts of  
364 interest to declare.

365

366 **Research Ethics**

367 This study used publicly available data to evaluate an intervention, which was not an RCT, so  
368 research ethics were not required.

369

370 **Data Availability Statement**

371 The raw data are publicly and freely available from Fingertips, <https://fingertips.phe.org.uk/>.

372 The cleaned dataset is available from the corresponding author upon reasonable request.

373

374 **Acknowledgments**

375 We would like to thank Professor Dame Sally Davies for her support in this project. Rohan  
376 Arambepola and Dr. Simon Taylor provided useful comments on the manuscript. The study  
377 was funded by Public Health England, where the authors were affiliated when doing this  
378 work. No other pharmaceutical company or agency paid for the work. The corresponding  
379 author had full access to all the data in the study and had final responsibility for the decision  
380 to submit for publication. The paper was presented at the 14<sup>th</sup> Annual Meeting of the Society  
381 for Behavioural Medicine, Reference 87.

382

383 **References**

384 <sup>1</sup>World Health Organization 2014. *Antimicrobial resistance: global report on surveillance*.  
385 [https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748\\_eng.pdf?sequence=](https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf?sequence=1)  
386 1

387 <sup>2</sup>The Review on Antimicrobial Resistance 2016. *Tackling Drug-Resistant Infections*  
388 *Globally: final report and recommendations*. [https://amr-](https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf)  
389 [review.org/sites/default/files/160525\\_Final%20paper\\_with%20cover.pdf](https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf)

390 <sup>3</sup>Davies SC, Fowler T, Watson J *et al*. Annual Report of the Chief Medical Officer: infection  
391 and the rise of antimicrobial resistance. *Lancet* 2013; **381**: 1606-9.

392 <sup>4</sup>Public Health England 2015. *Behaviour change and antibiotic prescribing in healthcare*  
393 *settings: Literature review and behavioural analysis*.

394 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/774129/Behaviour_Change_for_Antibiotic_Prescribing_-_FINAL.pdf)  
395 [/file/774129/Behaviour\\_Change\\_for\\_Antibiotic\\_Prescribing\\_-\\_FINAL.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/774129/Behaviour_Change_for_Antibiotic_Prescribing_-_FINAL.pdf)

396 <sup>5</sup>Hawker JI, Smith S, Smith GE *et al*. Trends in antibiotic prescribing in primary care for  
397 clinical syndromes subject to national recommendations to reduce antibiotic resistance, UK  
398 1995-2011: analysis of a large database of primary care consultations. *J Antimicrob*  
399 *Chemother* 2014; **69**: 3423-30.

400 <sup>6</sup>Public Health England 2014. *English Surveillance Programme for Antimicrobial Utilisation*  
401 *and Resistance (ESPAUR)*.

402 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/362374/ESPAUR_Report_2014__3_.pdf)  
403 [/file/362374/ESPAUR\\_Report\\_2014\\_\\_3\\_.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/362374/ESPAUR_Report_2014__3_.pdf)

404 <sup>7</sup>Smieszek T, Pouwels KB, Dolk FCK *et al*. Potential for reducing inappropriate antibiotic  
405 prescribing in English primary care. *J Antimicrob Chemother* 2018; **73** Suppl 2: ii36-43.

406 <sup>8</sup>HM Government 2014. *UK five year antimicrobial resistance (AMR) strategy 2013-2018:*  
407 *annual progress report and implementation plan*.

408 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/385733/UK_AMR_annual_report.pdf)  
409 [/file/385733/UK\\_AMR\\_annual\\_report.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/385733/UK_AMR_annual_report.pdf)

410 <sup>9</sup>Hallsworth M, Chadborn T, Sallis A, *et al*. Provision of social norm feedback to high  
411 prescribers of antibiotics in general practice: a pragmatic national randomised controlled trial.  
412 *Lancet* 2016; **387**: 1743–52.

413 <sup>10</sup>Royal College of General Practitioners 2019. *TARGET Antibiotic Toolkit*.  
414 <https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/target-antibiotic-toolkit.aspx>

415 <sup>11</sup>Australian Government, Department of Health 2018. *Nudge vs Superbugs: A behavioural*  
416 *economics trial to reduce the overprescribing of antibiotics*.  
417 [https://www1.health.gov.au/internet/main/publishing.nsf/Content/1598E371849EEA83CA25](https://www1.health.gov.au/internet/main/publishing.nsf/Content/1598E371849EEA83CA2582B000062D9C/$File/Nudge%20vs%20Superbugs%20-%20A%20behavioural%20economics%20trial%20to%20reduce%20the%20overprescribing%20of%20antibiotics%20June%202018.pdf)  
418 [82B000062D9C/\\$File/Nudge%20vs%20Superbugs%20-](https://www1.health.gov.au/internet/main/publishing.nsf/Content/1598E371849EEA83CA2582B000062D9C/$File/Nudge%20vs%20Superbugs%20-%20A%20behavioural%20economics%20trial%20to%20reduce%20the%20overprescribing%20of%20antibiotics%20June%202018.pdf)  
419 [%20A%20behavioural%20economics%20trial%20to%20reduce%20the%20overprescribing](https://www1.health.gov.au/internet/main/publishing.nsf/Content/1598E371849EEA83CA2582B000062D9C/$File/Nudge%20vs%20Superbugs%20-%20A%20behavioural%20economics%20trial%20to%20reduce%20the%20overprescribing%20of%20antibiotics%20June%202018.pdf)  
420 [%20of%20antibiotics%20June%202018.pdf](https://www1.health.gov.au/internet/main/publishing.nsf/Content/1598E371849EEA83CA2582B000062D9C/$File/Nudge%20vs%20Superbugs%20-%20A%20behavioural%20economics%20trial%20to%20reduce%20the%20overprescribing%20of%20antibiotics%20June%202018.pdf)

421 <sup>12</sup>Public Health Agency 2017. *Surveillance of Antimicrobial Use and Resistance in Northern*  
422 *Ireland, Annual Report*.  
423 [https://www.publichealth.hscni.net/sites/default/files/AMR\\_annual\\_report\\_final\\_0.pdf](https://www.publichealth.hscni.net/sites/default/files/AMR_annual_report_final_0.pdf)

424 <sup>13</sup>Government of Canada 2019. *Evidence synthesis summary: interventions to address*  
425 *antimicrobial use*. [https://www.canada.ca/en/public-health/services/publications/drugs-](https://www.canada.ca/en/public-health/services/publications/drugs-health-products/interventions-address-antimicrobial-use.html)  
426 [health-products/interventions-address-antimicrobial-use.html](https://www.canada.ca/en/public-health/services/publications/drugs-health-products/interventions-address-antimicrobial-use.html)

427 <sup>14</sup>Ontario Agency for Health Protection and Promotion 2019. *Providing Antibiotic*  
428 *Prescribing Feedback to Primary Care Physicians: The Ontario Program To Improve*  
429 *AntiMicrobial USE (OPTIMISE)*.  
430 [https://www.clinicaltrials.gov/ct2/show/study/NCT03776383?show\\_desc=Y#desc](https://www.clinicaltrials.gov/ct2/show/study/NCT03776383?show_desc=Y#desc)

431 <sup>15</sup>Behavioural Insights Team and UK Science & Innovation Network in France 2019.  
432 *Influencing behaviours through science: UK-France perspectives*.  
433 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/799398/FCO-BIT_conference_report_02MAY19.odt)  
434 [/file/799398/FCO-BIT\\_conference\\_report\\_02MAY19.odt](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/799398/FCO-BIT_conference_report_02MAY19.odt)

435 <sup>16</sup>Gould IM, Lawes T. Antibiotic stewardship: prescribing social norms. *Lancet* 2016;  
436 **387**:1699-701.

437 <sup>17</sup>HM Treasury 2011. *The Magenta Book: Guidance for evaluation*.  
438 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/220542/magenta_book_combined.pdf)  
439 [/file/220542/magenta\\_book\\_combined.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/220542/magenta_book_combined.pdf)

440 <sup>18</sup>Thistlethwaite DL, Campbell DT. Regression-discontinuity analysis: An alternative to the  
441 ex post facto experiment. *J Educ Psychol* 1960; **51**: 309-17.

442 <sup>19</sup>Lee DS, Lemieux T. Regression Discontinuity Designs in Economics. *J Econ Lit* 2010; **48**:  
443 281-355.

444 <sup>20</sup>MDRC 2013. *The Validity and Precision of the Comparative Interrupted Time Series*  
445 *Design and the Difference-in-Difference Design in Educational Evaluation*.  
446 [https://www.mdrc.org/sites/default/files/validity\\_precision\\_comparative\\_interrupted\\_time\\_se](https://www.mdrc.org/sites/default/files/validity_precision_comparative_interrupted_time_series_design.pdf)  
447 [ries\\_design.pdf](https://www.mdrc.org/sites/default/files/validity_precision_comparative_interrupted_time_series_design.pdf)

448 <sup>21</sup>Gelman A, Imbens G. Why High-Order Polynomials Should Not Be Used in Regression  
449 Discontinuity Designs. *J Bus Econ Stat* 2019; **37**: 447-56.

450 <sup>22</sup>Mitchell O, Cochran JC, Mears DP *et al*. Examining Prison Effects on Recidivism: A  
451 Regression Discontinuity Approach. *Justice Q* 2017; **34**: 571-96.

452 <sup>23</sup>Palmer M, Mitra S, Mont D *et al*. The impact of health insurance for children under age 6 in  
453 Vietnam: A regression discontinuity approach. *Soc Sci Med* 2015; **145**: 217-26.

454 <sup>24</sup>MDRC 2012. *A Practical Guide to Regression Discontinuity*.  
455 [https://www.mdrc.org/sites/default/files/regression\\_discontinuity\\_full.pdf](https://www.mdrc.org/sites/default/files/regression_discontinuity_full.pdf)

456 <sup>25</sup>R Core Team 2018. *R: A Language and Environment for Statistical Computing*.  
457 <http://www.R-project.org/>

458 <sup>26</sup>Dimmery D 2016. *Package 'rdd'*. <https://cran.r-project.org/web/packages/rdd/rdd.pdf>

459 <sup>27</sup>Imbens G, Kalyanaraman K. Optimal Bandwidth Choice for the Regression Discontinuity  
460 Estimator. *Rev Econ Stud* 2012; **79**: 933-59.

461 <sup>28</sup>NHS Business Services Authority 2019. *Prescribing data*.  
462 <https://www.nhsbsa.nhs.uk/prescription-data/prescribing-data>

463 <sup>29</sup>NHS Digital 2019. *GP and practice related data*.  
464 [https://digital.nhs.uk/services/organisation-data-service/data-downloads/gp-and-gp-practice-](https://digital.nhs.uk/services/organisation-data-service/data-downloads/gp-and-gp-practice-related-data)  
465 [related-data](https://digital.nhs.uk/services/organisation-data-service/data-downloads/gp-and-gp-practice-related-data)

466 <sup>30</sup>National Statistics 2015. *English indices of deprivation*.  
467 <https://www.gov.uk/government/statistics/english-indices-of-deprivation-2015>

468 <sup>31</sup>NHS Digital 2018. *Prescriptions Dispensed in the Community - Statistics for England, 2007-2017*. [https://files.digital.nhs.uk/14/832F9A/PDitC\\_2017\\_Appendix\\_Tables.xls](https://files.digital.nhs.uk/14/832F9A/PDitC_2017_Appendix_Tables.xls)

469 <sup>32</sup>NHS Business Services Authority 2017. *Amendments to the drug tariff April 2017*.  
470 [https://www.nhsbsa.nhs.uk/sites/default/files/2017-04/April\\_2017.pdf](https://www.nhsbsa.nhs.uk/sites/default/files/2017-04/April_2017.pdf)

471 <sup>33</sup>NHS Business Services Authority 2017. *Amendments to the drug tariff September 2017*.  
472 <https://www.nhsbsa.nhs.uk/sites/default/files/2017-08/September%202017.pdf>

473 <sup>34</sup>Guthrie B, Kavanagh K, Robertson C *et al*. Data feedback and behavioural change  
474 intervention to improve primary care prescribing safety (EFIPPS): multicentre, three arm,  
475 cluster randomised controlled trial. *BMJ* 2016; **354**: i4079.

476 <sup>35</sup>Tiefenbeck V, Tasic V, Schöb S *et al*. Long-lasting effects or Short-Term Spark? On the  
477 Persistence of behaviour Change induced by Real-Time feedback on Resource Consumption.  
478 In: *Research Papers of Twenty-Fourth European Conference on Information Systems (ECIS),*  
479 *Istanbul, Turkey, 2016*. Research Paper 84. Association for Information Systems, Atlanta,  
480 Georgia, USA.

481 <sup>36</sup>Ivers N, Jamtvedt G, Flottorp S *et al*. Audit and feedback: effects on professional practice  
482 and healthcare outcomes. *Cochrane Database Syst Rev* 2012; **6**: 1-229.

483 <sup>37</sup>Public Health England 2018. *English Surveillance Programme for Antimicrobial Utilisation*  
484 *and Resistance (ESPAUR)*.  
485 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/759975/ESPAUR_2018_report.pdf)  
486 [/file/759975/ESPAUR\\_2018\\_report.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/759975/ESPAUR_2018_report.pdf)

487 <sup>38</sup>Brehm JW. *A theory of psychological reactance*. Oxford: Academic Press, 1966.

488 <sup>39</sup>Dillard JP, Shen L. On the Nature of Reactance and its Role in Persuasive Health  
489 Communication. *Communication Monographs* 2005; **72**: 144–68.

490 <sup>40</sup>Steindl C, Jonas E, Sittenthaler S *et al*. Understanding Psychological Reactance: New  
491 Developments and Findings. *Z Psychol* 2015; **223**: 205–14.

492 <sup>41</sup>Aronson E, Turner JA, Carlsmith JM. Communicator credibility and communication  
493 discrepancy as determinants of opinion change. *J Abnorm Soc Psychol* 1963, **67**, 31-6.

494 <sup>42</sup>Pornpitakpan C. The Persuasiveness of Source Credibility: A Critical Review of Five  
495 Decades' Evidence. *J Appl Soc Psychol* 2004, **34**, 243-81.

496 <sup>43</sup>Henrich J, Heine SJ, Norenzayan A. Most people are not WEIRD. *Nature* 2010; **466**: 29.

497 <sup>44</sup>Gelfand MJ, Harrington JR. The Motivational Force of Descriptive Norms: For Whom and  
498 When Are Descriptive Norms Most Predictive of Behavior? *J Cross Cult Psychol* 2015; **46**:  
499 1273-78.

500 <sup>45</sup>Gelfand MJ, Raver JL, Nishii L *et al*. Differences Between Tight and Loose Cultures: A 33-  
501 Nation Study. *Science* 2011; **332**, 1100-4.

502 <sup>46</sup>World Health Organization 2018. *WHO report on surveillance of antibiotic consumption:*  
503 *2016-2018 early implementation*. [https://www.who.int/medicines/areas/rational\\_use/who-](https://www.who.int/medicines/areas/rational_use/who-amr-amc-report-20181109.pdf?ua=1)  
504 [amr-amc-report-20181109.pdf?ua=1](https://www.who.int/medicines/areas/rational_use/who-amr-amc-report-20181109.pdf?ua=1)

505  
506  
507  
508  
509  
510  
511  
512

513 **Table 1. Key differences between the six letter variants**

	<b>Previous letter</b>	<b>No previous letter</b>
	<i>Paragraph 2 starts:</i>	
	I have written to your practice previously and...	
<hr/>		
<b>Top 20%, prescribing not increasing</b>		
<i>Header:</i>		
Your practice is amongst the 20% highest prescribers of antibiotics nationally		
<i>Between Paragraph 1 and Paragraph 2:</i>	1A (Figure S1)	1B (Figure S2)
The great majority (80%) of practices in England prescribe fewer antibiotics per head than yours. Most other practices have reduced their prescribing rates since 2013/14 but yours has increased.		
<b>Top 20%, prescribing increasing</b>		
<i>Header:</i>		
Your practice is amongst the 20% highest prescribers of antibiotics nationally		
<i>Between Paragraph 1 and Paragraph 2:</i>	2A (Figure S3)	2B (Figure S4)
The great majority (80%) of practices in England prescribe fewer antibiotics per head than yours.		
<b>Top 10%</b>		
<i>Header:</i>		
Your practice is amongst the 10% highest prescribers of antibiotics nationally		
<i>Between Paragraph 1 and Paragraph 2:</i>	3A (Figure S5)	3B (Figure S6)
The great majority (90%) of practices in England prescribe fewer antibiotics per head than yours.		

514

515

516

517

518

519

520

521 **Table 2. Difference in prescribing rates between treatment and control**

	<b>Bandwidth</b>	<b>Number of observations</b>	<b>Estimate [95% CIs]</b>	<b>Standard error</b>	<b>z-value</b>	<b>P-value</b>	<b>Effect [95% CIs]</b>	<b>Predicted Change in Dispensed Items</b>
LATE*	0.523	6524	-0.016 [-0.010, -0.023]	0.003	-5.141	<0.001	-3.69% [-2.29, -5.10]	-124952 [-77544, -172698]
Half-bandwidth	0.262	4294	-0.015 [-0.007, -0.023]	0.004	-3.832	<0.001	-3.42% [-1.67, -5.17]	-115810 [-56550, -175069]
Double-bandwidth	1.047	6991	-0.014 [-0.008, -0.020]	0.003	-4.725	<0.001	-3.19% [-1.86, -4.51]	-108021 [-62984, -152720]

	<b>F-statistic</b>	<b>Numerator degrees of freedom</b>	<b>Denominator degrees of freedom</b>	<b>P-value</b>
LATE*	2185	3	6520	<0.001
Half-bandwidth	461	3	4290	<0.001
Double-bandwidth	4205	3	6987	<0.001

\* LATE = Local Average Treatment Effect and represents the optimal bandwidth.

522


523

524

525

526

527 **Figure 1. Discontinuity based on the most parsimonious model**



528

529 Note. The solid vertical black line represents the discontinuity threshold between the practices that received the

530 letter (right side of the line), versus the practices that did not (left side of the line). The two dotted lines  
 531 represent the LATE bandwidth thresholds. The solid black regression line represents the point-based estimates  
 532 of the RDD, whereas the two broken lines on either side of it represent 95% confidence intervals. Only 22 GP  
 533 practices in the 10% of highest prescribers were outside of the optimal bandwidth thresholds, indicating that the  
 534 bandwidth thresholds are unlikely to be the reason as to why the effects of the intervention were not detected  
 535 among these practices.

536 **Table 3. Deprivation adjusted difference in prescribing rates between treatment and control**

	Bandwidth	Number of observations	Estimate [95% CIs]	Standard error	z-value	P-value	Effect [95% CIs]	Predicted Change in Dispensed Items
LATE*	0.302	4814	-0.015 [-0.008, -0.022]	0.004	-4.105	<0.001	-3.40% [-1.78, -5.02]	-115132 [-60275, -169989]
Half-bandwidth	0.151	2546	-0.016 [-0.006, -0.026]	0.005	-3.081	0.002	-3.53% [-1.29, -5.78]	-119534 [-43683, -195725]
Double-bandwidth	0.604	6744	-0.015 [-0.009, -0.021]	0.003	-5.041	<0.001	-3.46% [-2.17, -4.81]	-117164 [-73481, -162878]
	F-statistic	Numerator degrees of freedom	Denominator degrees of freedom	P-value				
LATE*	530.6	4	4809	<0.001				
Half-bandwidth	69.76	4	2541	<0.001				
Double-bandwidth	2107.79	4	6739	<0.001				

\* LATE = Local Average Treatment Effect and represents the optimal bandwidth. Adjusted estimates are altered by the inclusion of a deprivation covariate (IMD-2015-based measure of population weighted average of the Lower Layer Super Output Areas covered by each practice).<sup>30</sup>

537  
538  
539

**Table 4. Deprivation adjusted difference in prescribing rates between treatment and control by letter**

Letter type (n)	LATE*	Bandwidth	Number of observations	Estimate [95% CIs]	Standard error	z-value	P-value	Effect [95% CIs]	Predicted Change in Dispensed Items
1A (n = 127)	Unadjusted	0.523	6524	-0.023 [-0.009, -0.037]	0.007	-3.157	0.002	-5.21% [-1.98, -8.45]	-17303 [-6576, -28063]
	Adjusted	0.302	4814	-0.026 [-0.011, -0.041]	0.008	-3.322	<0.001	-5.84% [-2.39, -9.28]	-19395 [-7937, -30820]
1B (n = 352)	Unadjusted	0.523	6524	-0.021 [-0.013, -0.029]	0.004	-5.205	<0.001	-4.75% [-2.96, -6.54]	-40416 [-25186, -55647]
	Adjusted	0.302	4814	-0.019 [-0.011, -0.028]	0.004	-4.398	<0.001	-4.41% [-2.44, -6.37]	-37523 [-20761, -54200]
2A (n = 290)	Unadjusted	0.523	6524	-0.010 [-0.002, -0.018]	0.004	-2.433	0.015	-2.32% [-0.45, -4.18]	-16822 [-3263, -30308]
	Adjusted	0.302	4814	-0.009 [-0.0003, -0.018]	0.005	-2.026	0.043	-2.10% [-0.07, -4.13]	-15227 [-508, -29946]
2B (n = 289)	Unadjusted	0.523	6524	-0.017 [-0.008, -0.025]	0.004	-3.830	<0.001	-3.81% [-1.86, -5.76]	-28383 [-13856, -42910]
	Adjusted	0.302	4814	-0.014 [-0.004, -0.023]	0.005	-2.898	0.004	-3.14% [-1.02, -5.27]	-23392 [-7599, -39260]
3A (n = 250)	Unadjusted	0.523	6524	-0.009 [0.003, -0.022]	0.007	-1.442	0.150	-2.13% [0.76, -5.02]	-12445 [4440, -29330]
	Adjusted	0.302	4814	-0.007 [0.007, -0.021]	0.007	-0.932	0.352	-1.51% [1.67, -4.68]	-8822 [9757, -27344]
3B (n = 70)	Unadjusted	0.523	6524	0.007 [0.032, -0.019]	0.013	0.500	0.617	1.47% [7.24, -4.30]	2190 [10784, -6405]
	Adjusted	0.302	4814	0.006 [0.031, -0.020]	0.013	0.448	0.654	1.31% [7.04, -4.42]	1951 [10486, -6583]

---

\* LATE = Local Average Treatment Effect calculated using the optimal bandwidth for a given RDD. Adjusted estimates are altered by the inclusion of a deprivation covariate (IMD-2015-based measure of population weighted average of the Lower Layer Super Output Areas covered by each practice).<sup>30</sup> n = number of practices that received each letter.